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Summary High response rates in patients with metastatic melanoma have been achieved with combination chemoimmunotherapy. A
response rate of 62% in 45 patients has been reported for treatment with dacarbazine, bleomycin, vincristine, lomustine (BOLD) plus
interferon ax (IFN-ax). We conducted a multicentre phase 11 study to confirm these results. Melanoma patients with distant metastases were
treated as outpatients with dacarbazine 200 mg m-2 on days 1-5, vincristine 1 mg m-2 on days 1 and 4, bleomycin 15 mg on days 2 and 5 i.v.
and lomustine 80 mg orally on day 1, repeated every 4 weeks. IFN-a-2b was initiated s.c. on day 8 at 3 MU daily for 6 weeks, and 6 MU t.i.w.
thereafter. Forty-three patients entered the study. The median number of metastatic sites was three (range 1-5), and 81% of patients had
visceral metastases. Nine patients had brain metastases, and seven patients were systemically pretreated. Among the 41 patients that were
evaluable for response, the response rate was 27% (95% Cl 14-43%), with one complete and ten partial remissions. The response rate in 25
previously untreated patients without brain metastases was 40% (95% Cl 21-61%). Median duration of response was 6 (range 2-14+)
months; median overall survival was 5 (1-26) months. The main toxicity was malaise/fatigue. We confirm that BOLD plus IFN-aX has activity
in metastatic melanoma. The lower response rate in our study compared with the previous report is probably related to patient selection,
as in the previous study 46% of patients had stage IlIl disease, whereas all our patients had stage IV disease, which is associated with a
worse prognosis.
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Although long-term remissions have been achieved in patients
with metastatic melanoma, the regimen of choice remains contro-
versial in these patients. Single-agent therapy with dacarbazine
(DTIC) or immunotherapeutic agents such as interleukin 2 (IL-2)
and interferon-tx (IFN-ax) results in response rates of 15-20%
(Houghton et al, 1992; Kirkwood, 1995; Marincola and Rosenberg,
1995). With combination chemotherapy regimens, such as
cisplatin, vinblastine and DTIC (CVD) (Legha et al, 1989) or
cisplatin, carmustine, DTIC and tamoxifen (Del Prete et al, 1984;
McClay et al, 1992), response rates of 40-52% have been
observed. The response rate of 40% initially reported for
bleomycin, vincristine, lomustine and DTIC (BOLD) (Seigler et al,
1980) was not confirmed by others (York and Foltz, 1988;
Prudente Foundation Melanoma Study Group, 1989). Combination
immunotherapy with IL-2 and IFN-ax has not unequivocally
improved the results of either agent alone (Kirkwood, 1995) and
was very toxic when administered at high doses (Kruit et al, 1994;
Marincola et al, 1995; Kruit et al, 1996). Several chemoim-
munotherapy schedules have been clinically tested. The results of
DTIC plus IFN-ax are conflicting, with most trials failing to show a
benefit of the combination over DTIC alone (Falkson et al, 1991;
Thompson et al, 1993; Bajetta et al, 1994; Mulder et al, 1994;
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Falkson et al, 1996). Phase II results of DTIC plus IL-2 did not
suggest a clear benefit for this combination (Stoter et al, 1991;
Fiedler et al, 1992). High response rates of 42-73% have been
achieved in (mostly single centre) phase II studies with combina-
tions ofIL-2, IFN-ax and cisplatin (Khayat et al, 1993), IL-2, IFN-
ax and CVD (Buzaid and Legha, 1994), IL-2, cisplatin, DTIC and
tamoxifen (Atkins et al, 1994), and IL-2, IFN-ax, cisplatin, carmus-
tine, DTIC and tamoxifen (Richards et al, 1992). The median dura-
tion ofresponse and survival in these studies was reported to be up
to 9 months and 14 months respectively.
Pyrhonen et al, (1992) reported a 62% response rate (95% confi-
dence limit 48-77%) with 13% complete responses in 45 patients
upon combination treatment consisting ofBOLD plus IFN-ax. Two
patients with stable disease and two with progressive disease
responded when the administration of IFN-ax was changed from a
weekly to an intermittent schedule. There was one toxic death, but
overall toxicity was acceptable. Given these promising results, we
performed a confirmatory study with the same schedule in patients
with metastatic melanoma.
PATIENTS AND METHODS
Eligibility
Eligibility criteria included histologically proven metastatic
melanoma, not amenable to surgery, bidimensionally measurable
disease, WHO performance status 0-2, age 18-75 years, pretreat-
ment with a maximum of one regimen containing < 1 drug of the
proposed regimen, serum values of creatinine < 150 fmol 1-1,
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Table 1 Patients' characteristics
Characteristics No. of patients
Total number of patients, men/women 43, 27/16
Primary melanoma of skin/uvea 42/1
Median age, years (range) 58 (22-74)
WHO performance status
0 13
1 18
2 12
Median serum LDH, U I-' (range) 369 (161-4768)
Prior therapy
Systemic treatment 7
IL-2 + IFN-a + cisplatin 3
IL-2 + IFN-a 2
DTIC 2
Regional limb perfusion 1
Radiotherapy 8
Surgery for metastases 9
Disease sites
Lungs 24
Lymph nodes 24
Skin/subcutaneous 22
Liver 17
Brain 9
Bone 5
Other 10
No. of disease sites
1 8
2 13
3 11
4 5
5 6
bilirubin < 25 ,umol 1-1, liver transaminases < 1.5 times normal
unless related to liver metastases, WBC 23.5 x 109 1-1 and
platelets . 100 x 1091-1. Patients with a history of second malig-
nancy, with the exception of adequately treated carcinoma in situ
of the cervix or basal/squamous cell carcinoma of the skin,
concomitant serious non-malignant illness, active infections,
concurrent treatment with immunosuppressive agents and preg-
nant or lactating women were excluded. Patients with asympto-
matic brain metastases were eligible provided they were not
receiving treatment with steroids. Written informed consent was
obtained from all patients. Before initiation of this trial, institu-
tional review board approval was obtained at each of the
participating centres.
Study design
Patients were treated as outpatients with chemotherapy (BOLD)
consisting oflomustine 80 mg administered orally on day 1, DTIC
200 mg m-2 i.v. on days 1-5, bleomycin 15 mg i.v. on days 2 + 5,
and vincristine 1 mg m-2 i.v. on days 1 + 4. Cycles were repeated
every 4 weeks. IFN-a-2b (Intron A, Schering Plough, The
Netherlands) was administered s.c. at 3 MU daily for 6 weeks
starting at day 8 and 6 MU t.i.w. thereafter. Patients received
prophylactic antiemesis with 5HT3 antagonists during the 5 days
of chemotherapy administration. The use of corticosteroids was
prohibited. Before and after IFN-oc administration, patients
received acetaminophen 1000 mg orally. The addition ofnaproxen
Table 2 Grade 3/4 toxicity in 42 evaluable patients
Toxicity Grade 3 Grade 4 Total no. of patients(%)
Malaise/fatigue 14 14 (33)
Alopecia 9 9 (21)
Anorexia 6 6 (14)
Nausea 5 0 5 (12)
Vomiting 1 0 1 (2)
Lung 1 0 1(2)
Neuropsychiatric 1 0 1 (2)
Stomatitis 0 1 1 (2)
Diarrhoea 1 0 1 (2)
Myalgia 1 1 (2)
Leucocytopenia 8 0 8 (19)
Anaemia 2 0 2 (5)
Thrombocytopenia 1 0 1 (2)
Death 1a 1(2)
Toxicity according to WHO criteria: 1, mild; 2, moderate; 3, severe; 4, life-
threatening. Numbers are patients. aSudden death on fifth day of first cycle -
a causal relationship with treatment was unclear.
250 mg for constitutional symptoms caused by IFN-a was
allowed. Patients were evaluated weekly for toxicity and every
two cycles for response. WHO criteria for toxicity and response
were used. Treatment was continued in the absence of tumour
progression or severe toxicity. In the case ofWHO grade 3 toxici-
ties, treatment was withheld until complete resolution of the toxi-
city, and the dose of the responsible drug was reduced to 75% in
subsequentcycles. Chemotherapy cycles were only restarted when
WBC and platelet values were > 3.5 x 109 1-' and 100 x 109 1-
respectively. In the case of WHO . grade 3 vincristine-induced
neurotoxicity or bleomycin-induced pulmonary toxicity, these
drugs were permanently discontinued. A 50% dose reduction of
IFN-a was allowed for 2grade 3 constitutional symptoms.
RESULTS
Forty-three patients were entered onto the study in seven different
centres. Patients' characteristics are listed in Table 1. All patients
had stage IV disease, i.e. with distant metastases. The median age
of all patients was 58 years (range 22-74), median WHO perfor-
mance status 1 (0-2), median serum lactate dehydrogenase (LDH)
369 U 1-' (161-4768, normal values up to 330 U [-'). The median
number of metastatic sites was 3 (1-5). The sites of metastases
were the lungs in 24 patients, lymph nodes in 24, skin/subcuta-
neous in 22, liver in 17, brain in nine, bone in five and other sites
in ten patients. Visceral metastases were present in 81% of
patients. Seven patients had received prior systemic treatment,
eight had received prior radiotherapy and nine had had surgery
for metastases. Patients received a median number of two (range
1-8) cycles.
Anti-tumour responses
Two patients were not evaluable for response. One patient died
suddenly on the fifth day of treatment and one patient refused
treatment after one cycle and was subsequently lost to follow-up.
Thus, 41 patients were evaluable for response. The overall
response rate was 27% (95% CI 14-43%) with one CR and ten
PRs. No responses occurred in the seven patients who had been
systemically pretreated. Ofthe ninepatients with brain metastases,
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one PR occurred in a patient who had received prior cranial irradi-
ation, whereas all four patients with asymptomatic brain meta-
stases who were not previously irradiated progressed at this site.
The response rate in 25 previously systemically untreated patients
without brain metastases was 40% (95% CI 21-61%). Responses
occurred in the lungs, skin/subcutaneous, lymph nodes, liver,
spleen, and adrenal metastases. Median response duration was 6
months (range 2-14+ months). Median overall survival was 5
months (1-26), and in the 25 patients without prior systemic treat-
ment and brain metastases 6 months (1-26). In four patients with
progressive disease the BOLD regimen was continued, but IFN-a
was given intermittently in 2-week periods interrupted by a
2-week rest period. In contrast to the original report (Pyrhonen
et al, 1992), no responses or disease stabilizations were seen in
these patients.
Clinical toxicities
Forty-two patients were evaluable for toxicity. Grade 3/4 toxicity
(WHO) occurred in 28 (67%) patients and consisted mainly of
fatigue (33%), anorexia (14%), leucocytopenia (19%) and nausea
(12%) (Table 2). A 72-year-old man with a partial response oflung
metastases and a complete response of liver, subcutaneous and
lymph node metastases developed pulmonary fibrosis with dys-
pnoea at rest after the third chemotherapy cycle. Treatment was
discontinued and treatment with corticosteroids was instituted,
after which his condition remained stable. He died 6 months later
of brain metastases. A 59-year-old female patient with a partial
response of lung metastases experienced a severe depression,
which was quickly reversible after discontinuation of IFN-a.
BOLD was continued for a total of six cycles. She died after 20
months of tumour progression. A 67-year-old man died suddenly
at home on the fifth day of the first chemotherapy cycle before
treatment with IFN-ca was initiated. A tentative diagnosis of a
myocardial infarction was made, and a definite causal relationship
with treatment could not be established. Toxicity necessitated dose
reductions or discontinuation ofBOLD chemotherapy in 16 out of
134 cycles (12%) in eight patients (19%), and chemotherapy was
delayed in 12 out of 134 cycles (9%) in ten patients (24%). The
dose ofIFN-a was reduced or discontinued in six patients (14%).
DISCUSSION
The mechanisms underlying the supposed synergistic interaction
between chemotherapy and immunotherapy are still speculative.
Arguments for the enhancement of the anti-tumour activity of
immunotherapy by chemotherapy as well as vice versa have been
postulated. Clinical support for an interaction between these treat-
ment modalities comes from the observation that the sequence
of administration of these treatment modalities appears to be
an important factor (Buzaid and Legha, 1994). Furthermore,
increasing CD4/CD8 ratios during chemoimmunotherapy with
BOLD plus IFN-a have been correlated with response, implying
the stimulation of host defence mechanisms (Hernberg et al,
1996). The response rate with BOLD plus IFN-a in patients with
metastatic melanoma in our study of 27% (95% CI 14-43%) for
all patients and 40% (95% CI 21-61%) for patients without prior
systemic treatment and brain metastases are lower than reported
by Pyrhonen et al, (1992), who used the same doses and schedule.
This difference might be explained by two factors. First, the source
of IFN-a differed in the two studies. We used recombinant IFN-a-
2b whereas Pyrhonen et al, used purified human leucocyte IFN-a
from the Finnish Red Cross Blood Transfusion Service (Cantell et
al, 1981). However, a clinical advantage for a specific type ofIFN-
a has never been demonstrated. Second, there are important differ-
ences between the patient populations of the two studies. In the
study of Pyrhonen et al, (1992), 22 of the 48 patients (46%) had
stage III disease, whereas all our patients had stage IV disease. For
stage III melanoma patients with regional lymph node metastases,
surgery with regional radical lymphadenectomy is the treatment of
choice, and for patients with intransit metastases of an extremity
isolated limb perfusion is preferred. For therapeutic groin dissec-
tions in stage III patients, 5-year survival rates of 30-47% have
been reported, depending on the involvement ofdeep nodes (Kara-
kousis et al, 1986). In the worst group of stage III patients, i.e. with
both regional node and in-transit metastases, the 5-year survival
may be 19% and the median survival time 17 months (Singletary
and Balch, 1992). This is in contrast to stage IV patients with non-
visceral and visceral metastases, who may have a 1-year-survival
rate of 46% and 18% respectively and median survival times of
8 and 3 months respectively (Balch et al, 1992). Furthermore,
71% of our patients had a WHO performance status of < 1,
whereas this was the case for 92% of patients in the study by
Pyrhonen et al (1992). Another aspect associated with poor prog-
nosis was the median number of three metastatic sites in patients
from our study, and in a previous review no patients with this char-
acteristic survived for more than 1 year (Balch et al, 1992). It can
therefore be concluded that our patient population consisted of a
group with a worse prognosis than those in the study by Pyrhonen
et al (1992). In that study, 10% of patients had brain metastases
and several patients had been systemically pretreated. The median
duration of response was not different between the two studies,
being 6 months in our study and 6.8 months in the study of
Pyrhonen et al (1992). Although tested in only four patients, we
could not observe any disease regression in non-responders upon
changing the IFN-a administration to an intermittent schedule
(Pyrhonen et al, 1992).
The most common severe toxicity in our study was IFN-a-
related malaise and fatigue, which occurred in 33% of patients.
This occurred in 20% of patients in the study by Pyrhonen et al,
(1992). Surprisingly, patients in this last study experienced more
grade 3/4 haematological toxicity than in our study (leuco-
cytopenia and thrombocytopenia 17% and 2% vs 32% and 11%
respectively). Whether this reflects the difference in the source of
IFN-a is uncertain.
In conclusion, we confirm that BOLD plus IFN-a is an active
regimen in patients with metastatic melanoma. The previous
reported high response rate of 62% in 48 patients is probably
related to a selection of patients with good prognosis. The median
survival of 6 months in this group of patients is disappointing but
may be related to poor prognostic parameters.
To date, the combination of immunotherapy (IFN-a and/or IL-
2) with multidrug chemotherapy (mostly including DTIC and
cisplatin) has yielded the highest response rates in metastatic
melanoma, with response rates up to 70% (Pyrhonen et al, 1992;
Richards et al, 1992; Khayat et al, 1993; Atkins et al, 1994; Buzaid
and Legha, 1994). However, all these results were obtained in
(mostly single centre) phase II studies. Recently, it has been
demonstrated in the setting of a randomized phase III trial in
metastatic melanoma that the addition of cisplatin to a regimen of
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IL-2 and IFN-x significantly increases the response rate without
prolonging survival (Keilholz et al, 1996). In order to provide
patients with metastatic melanoma with the best possible care,
further randomized phase III trials are warranted to establish the
value of combination treatments vs less intensive and therefore
less toxic regimens.
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